La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
BrightGene Bio-Medical Technology Bilan de santé
Santé financière contrôle des critères 3/6
BrightGene Bio-Medical Technology has a total shareholder equity of CN¥2.5B and total debt of CN¥2.2B, which brings its debt-to-equity ratio to 89.3%. Its total assets and total liabilities are CN¥5.1B and CN¥2.6B respectively. BrightGene Bio-Medical Technology's EBIT is CN¥211.6M making its interest coverage ratio 6.8. It has cash and short-term investments of CN¥1.0B.
Informations clés
89.3%
Ratio d'endettement
CN¥2.21b
Dette
| Ratio de couverture des intérêts | 6.8x |
| Argent liquide | CN¥1.04b |
| Fonds propres | CN¥2.47b |
| Total du passif | CN¥2.61b |
| Total des actifs | CN¥5.09b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01Analyse de la situation financière
Passif à court terme: 688166's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥999.3M).
Passif à long terme: 688166's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥1.6B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 688166's net debt to equity ratio (47.4%) is considered high.
Réduire la dette: 688166's debt to equity ratio has increased from 0% to 89.3% over the past 5 years.
Couverture de la dette: 688166's debt is not well covered by operating cash flow (14.4%).
Couverture des intérêts: 688166's interest payments on its debt are well covered by EBIT (6.8x coverage).